The path to appropriate biosimilar management by Jim Rebello May 10, 2021Biosimilar, Biosimilar Management, Biosimilars, FDA, Magellan Health, Magellan Healthcare, Magellan RX, Magellan Rx Management, Medical Benefit, Oncology Biosimilars, Specialty Pharmacy
What do Employers Need to Know about Escalating Specialty Drug Spend? by Kathy Campagna May 24, 2017Autoimmune, Employers, Magellan Rx Management, Medical Benefit, Oncology, PBM, Rare Diseases, Specialty Pharmacy
How Can You Better Understand The Impact of High-Cost Specialty Drugs Billed on the Medical Benefit? by Magellan Health Insights April 12, 2017Casandra Stockman, Medical Benefit, PBM, Specialty Pharmacy
